• 23andMe is set to release its quarterly earnings with an expected EPS of -$0.16 and projected revenue of $54.3 million.
• The company announces a significant restructuring, including a 40% workforce reduction to save over $35 million annually.
• Despite financial challenges, 23andMe maintains a moderate debt-to-equity ratio of 0.52 and a current ratio of 1.49.

23andMe Holding Co. (NASDAQ: ME) is a key player in the human genetics and preventive health industry. The company is known for its genetic testing services, which provide insights into ancestry and health predispositions. As a competitor in the biopharmaceutical sector, 23andMe faces competition from companies like AncestryDNA and MyHeritage.

ME is set to release its quarterly earnings on Tuesday, November 12, 2024, at 8:30 AM Eastern Standard Time. Wall Street estimates the earnings per share to be -$0.16, with projected revenue of approximately $54.3 million. This comes amid a significant business restructuring aimed at streamlining operations and reducing costs.

The restructuring involves a 40% workforce reduction, expected to save over $35 million annually. This move is part of 23andMe’s strategy to focus on core operations and future growth. The company will also discontinue its therapeutics division, seeking strategic alternatives for its in-house programs.

Financially, ME is experiencing challenges, as indicated by a negative price-to-earnings (P/E) ratio of -3.62. This suggests the company is currently not profitable. The price-to-sales ratio of 0.60 indicates that the market values the company’s sales at 60 cents for every dollar of sales.

Despite these challenges, 23andMe maintains a moderate debt-to-equity ratio of 0.52, suggesting a balanced approach to leveraging debt. The current ratio of 1.49 indicates that the company has sufficient liquidity to cover its short-term liabilities, providing some financial stability amid its restructuring efforts.